Scarica l'app Stockscreener
11.12
2.77%
0.30
Dopo l'orario di chiusura:
11.17
0.05
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$10.82
Aprire:
$10.96
Volume 24 ore:
2.93M
Relative Volume:
0.87
Capitalizzazione di mercato:
$2.91B
Reddito:
$6.41B
Utile/perdita netta:
$1.30B
Rapporto P/E:
2.2063
EPS:
5.04
Flusso di cassa netto:
$646.00M
1 W Prestazione:
-2.71%
1M Prestazione:
-28.81%
6M Prestazione:
-36.96%
1 anno Prestazione:
-37.77%
Intervallo 1D:
$10.88
$11.22
Intervallo di 1 settimana:
$10.75
$11.66
Portata 52W:
$10.75
$23.10
Organon Co Stock (OGN) Company Profile
Nome
Organon Co
Settore
Industria
Telefono
551-430-6000
Indirizzo
30 HUDSON STREET, JERSEY CITY
Confronta OGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
11.12 | 2.91B | 6.41B | 1.30B | 646.00M | 5.04 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-21 | Iniziato | Barclays | Overweight |
| 2023-03-16 | Iniziato | Raymond James | Outperform |
| 2022-10-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Iniziato | Piper Sandler | Neutral |
| 2021-09-01 | Iniziato | BofA Securities | Buy |
| 2021-07-22 | Iniziato | Citigroup | Buy |
| 2021-06-15 | Iniziato | JP Morgan | Neutral |
| 2021-06-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Organon Co Borsa (OGN) Ultime notizie
(OGN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ganirelix Market Is Booming Worldwide 2025-2032 | Organon & Co.,Merck & Co., Inc.,Ferring Pharmaceuticals - openPR.com
Organon stock hits 52-week low at $10.92 amid market challenges By Investing.com - Investing.com South Africa
Organon stock hits 52-week low at $10.92 amid market challenges - Investing.com Australia
Organon expands board with new director from Takeda - Investing.com
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Bluefield Daily Telegraph
Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan
Organon & CoExpects $6 Million Milestone Expense In Q1 2025 - MarketScreener
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Bluefield Daily Telegraph
Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan
Organon (OGN) Laps the Stock Market: Here's Why - Yahoo Finance
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - MarketScreener
Organon's NDURVA Cream Gets Health Canada Approval for Plaque Psoriasis Treatment - MarketScreener
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 뉴스와이어
Organon's Ba2 CFR affirmed by Moody's, outlook revised to negative - Investing.com Australia
Organon’s Ba2 CFR affirmed by Moody’s, outlook revised to negative - Investing.com Canada
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? - Nasdaq
Organon (OGN) Sees Flat Revenue, Downgraded Full-Year Outlook - GuruFocus
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Organon Enters Oversold Territory - Nasdaq
Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune
Organon stock hits 52-week low at $13.84 amid market challenges - Investing.com Canada
Organon stock hits 52-week low at $13.84 amid market challenges By Investing.com - Investing.com South Africa
Organon (OGN) Stock Moves -1.83%: What You Should Know - Yahoo Finance
Why Organon (OGN) Could Beat Earnings Estimates Again - Yahoo Finance
Organon acquires Actemra biosimilar’s US rights from Biogen - Pharmaceutical Technology
Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com
Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com South Africa
Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive
Organon Acquires TOFIDENCE - citybiz
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon Acquires Tofidence for Intravenous Infusion in US - MarketScreener
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha
Organon acquires rights for Tofidence from Biogen - TipRanks
Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Bluefield Daily Telegraph
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan
Natixis Advisors LLC Decreases Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Organon (OGN) Stock Moves -0.34%: What You Should Know - Yahoo Finance
Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug - MarketScreener
European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11 - MarketScreener
Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11 - TipRanks
Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success - Stock Titan
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Organon & Co. (OGN): A Deep Value Play with a 35.96% Upside Potential and an Attractive 7.61% Dividend Yield - DirectorsTalk Interviews
Connor Clark & Lunn Investment Management Ltd. Purchases New Position in Organon & Co. (NYSE:OGN) - MarketBeat
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price - simplywall.st
Organon Co Azioni (OGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):